# Pulmatrix, Inc.

Pulmatrix, Inc. is a public company headquartered in Framingham, MA, United States.

## Company overview

- **Legal name:** Pulmatrix, Inc.
- **Former names in filing history:** Ruthigen, Inc. (2013-05-24 to 2015-06-16)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Framingham, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001574235

## About

Pulmatrix developed inhaled drug candidates using iSPERSE, an engineered dry-powder delivery platform. Its investigational programs addressed migraine and respiratory conditions, including chronic obstructive pulmonary disease and allergic bronchopulmonary aspergillosis. In its annual filing published in February 2026, the company reported that development was paused while it pursued monetization opportunities. Its March 26, 2026 agreement for a proposed Eos merger was subject to approvals and other closing conditions. Its reported principal executive office is in Framingham, MA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included a net loss of USD 5,162,000; cash used in operations of USD 5,433,000. At that year-end, it reported total assets of USD 4,139,000 and cash and cash equivalents of USD 4,088,000.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Net income:** -$5.2M (USD -5,162,000)
- **Total assets:** $4.1M (USD 4,139,000)
- **Cash and equivalents:** $4.1M (USD 4,088,000)
- **Operating cash flow:** -$5.4M (USD -5,433,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $7.8M (USD 7,806,000)
- **Net income:** -$9.6M (USD -9,559,000)
- **Total assets:** $9.9M (USD 9,943,000)
- **Cash and equivalents:** $9.5M (USD 9,521,000)
- **Operating cash flow:** -$10.7M (USD -10,716,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $7.3M (USD 7,298,000)
- **Net income:** -$14.1M (USD -14,121,000)
- **Total assets:** $34.0M (USD 33,958,000)
- **Cash and equivalents:** $19.2M (USD 19,173,000)
- **Operating cash flow:** -$16.0M (USD -15,985,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $6.1M (USD 6,071,000)
- **Net income:** -$18.8M (USD -18,836,000)
- **Total assets:** $41.0M (USD 40,953,000)
- **Cash and equivalents:** $35.6M (USD 35,628,000)
- **Operating cash flow:** -$19.4M (USD -19,356,000)

## Recent SEC filings

- Form 10-Q — filed 2026-08-13 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-13 — period 2026-08-13 — 8-K
- Form S-4 — filed 2026-07-09 — S-4
- Form 10-K/A — filed 2026-06-16 — period 2025-12-31 — 10-K/A
- Form 10-Q — filed 2026-05-15 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-15 — period 2026-05-15 — 8-K
- Form 8-K — filed 2026-04-21 — period 2026-04-16 — 8-K
- Form 8-K — filed 2026-03-27 — period 2026-03-26 — 8-K
- Form 8-K — filed 2026-03-02 — period 2026-02-28 — 8-K
- Form 10-K — filed 2026-02-26 — period 2025-12-31 — 10-K
- Form 8-K — filed 2026-02-26 — period 2026-02-26 — 8-K
- Form 8-K — filed 2025-12-18 — period 2025-12-17 — 8-K

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/pulmatrix-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology